[go: up one dir, main page]

BR9913340A - Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal - Google Patents

Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal

Info

Publication number
BR9913340A
BR9913340A BR9913340-7A BR9913340A BR9913340A BR 9913340 A BR9913340 A BR 9913340A BR 9913340 A BR9913340 A BR 9913340A BR 9913340 A BR9913340 A BR 9913340A
Authority
BR
Brazil
Prior art keywords
proteins
vaccine
composition
fragments
fragment
Prior art date
Application number
BR9913340-7A
Other languages
English (en)
Inventor
Joseph M Patti
Timothy J Foster
Magnus Hook
Original Assignee
Inhibitex Inc
Texas A & M Univ Sys
Trinity College Dublin
Undivided Trinity Of Queen Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc, Texas A & M Univ Sys, Trinity College Dublin, Undivided Trinity Of Queen Eli filed Critical Inhibitex Inc
Publication of BR9913340A publication Critical patent/BR9913340A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO, VACINA, E, PROCESSOS DE GERAR UMA RESPOSTA IMUNE, E DE INIBIR A COLONIZAçãO MICROBIANA EM UM ANIMAL". Vacinas de multicomponente são fornecidas que auxiliam na prevenção e no tratamento de infecções estafilocóccicas e que incluem certas combinações selecionadas de proteinas de ligação bacteriana ou seus fragmentos ou anticorpos para estas proteinas ou fragmentos. Pela seleção cuidadosa das proteinas, fragmentos ou anticorpos, uma vacina é fornecida que comunica proteção contra um amplo espectro de cepas bacterianas de Staphylococcus e contra proteínas que são expressadas em diferentes estágios da curva logarítmica de desenvolvimento. Em uma modalidade da invenção, uma composição é fornecida que inclui pelo menos uma proteína ou peptídeo de ligação de collogen (ou uma sequência mutada direcionada a sítio apropriado destes) tal como CNA ou uma proteina ou fragmento com homologia suficientemente alta a estas, em combinação com uma proteína de ligação de fibrogeno, preferivelmente o fator A de aglutinação ("ClfA") ou o fator B de aglutinação ("ClfB") ou um fragmento utilizável destes ou uma proteína ou fragmento com homologia suficientemente alta a estas. As vacinas e os produtos da presente invenção são vantajosos em que respondem à urgente necessidade da comunidade médica para um substituto para antibióticos de molécula pequena, que perdem rapidamente a eficácia e fornecem combinações eficazes do grande número de adesinas de superfície bacteriana conhecidas que podem comunicar proteção eficaz contra um amplo espectro de infecções bacterianas.
BR9913340-7A 1998-08-31 1999-08-31 Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal BR9913340A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9843998P 1998-08-31 1998-08-31
PCT/US1999/019727 WO2000012131A1 (en) 1998-08-31 1999-08-31 Multicomponent vaccines

Publications (1)

Publication Number Publication Date
BR9913340A true BR9913340A (pt) 2001-11-06

Family

ID=22269290

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913340-7A BR9913340A (pt) 1998-08-31 1999-08-31 Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal

Country Status (13)

Country Link
EP (1) EP1109577B1 (pt)
JP (2) JP2002523473A (pt)
KR (1) KR100644953B1 (pt)
CN (1) CN1314450C (pt)
AT (1) ATE422368T1 (pt)
AU (1) AU771426B2 (pt)
BR (1) BR9913340A (pt)
CA (2) CA2777661C (pt)
DE (1) DE69940404D1 (pt)
ES (1) ES2322409T3 (pt)
IL (1) IL141639A (pt)
MX (1) MXPA01002119A (pt)
WO (1) WO2000012131A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762978B2 (en) * 1998-08-31 2003-07-10 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
MXPA01002120A (es) 1998-08-31 2003-03-27 Trinity College Dublin Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa.
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
DE60134881D1 (de) * 2000-10-20 2008-08-28 Inhibitex Inc Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
CA2478029A1 (en) * 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
CN102366630B (zh) * 2003-03-07 2015-04-01 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
US20070053925A1 (en) * 2003-04-16 2007-03-08 Eric Brown Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation
EP1631581A4 (en) * 2003-05-29 2006-10-18 Inhibitex Inc SDR PROTEINS FROM STAPHYLOCOCCUS CAPITIS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF INFECTIONS
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP1832654B1 (en) * 2004-12-28 2011-07-27 Sekisui Medical Co., Ltd. Anti-human soluble fibrin monoclonal antibody and immunological assay method using the antibody
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
SG185299A1 (en) * 2007-07-23 2012-11-29 Vaccine Res Internat Plc Inactivated staphylococcal whole-cell vaccine
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2414387B1 (en) 2009-04-03 2015-12-16 University Of Chicago Compositions and methods related to protein a (spa) variants
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
EP2445523B1 (en) 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
PT2445522T (pt) 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
TWI502068B (zh) 2009-07-15 2015-10-01 Aimm Therapiutics B V 革蘭氏陽性菌特異性結合的化合物
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
MX339146B (es) 2009-12-15 2016-05-13 Novartis Ag Suspension homogenea de compuestos inmunopotenciadores y usos de los mismos.
EA023725B1 (ru) 2010-03-23 2016-07-29 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103826656B (zh) * 2010-12-22 2015-08-26 惠氏有限责任公司 金黄色葡萄球菌抗原的稳定的免疫原性组合物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2848257A4 (en) * 2012-05-07 2015-12-02 Mogam Biotechnology Inst VACCINE COMPOSITION FOR PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
US20170281744A1 (en) * 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
CN107007832A (zh) * 2016-01-28 2017-08-04 中创云牧科技咨询(北京)股份有限公司 一种ClfA-A靶位的金黄色葡萄球菌奶牛乳房炎疫苗的制备方法
KR102895036B1 (ko) 2018-02-12 2025-12-03 이니뮨 코퍼레이션 톨-유사 수용체 리간드
JP7643730B2 (ja) 2019-05-14 2025-03-11 ザ・ユニバーシティ・オブ・シカゴ ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
IL302449A (en) 2020-11-04 2023-06-01 Eligo Bioscience CUTIBACTERIUM ACNES PHAGES RECOMBINANT, the production method and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US5440014A (en) * 1990-08-10 1995-08-08 H+E,Uml/Oo/ K; Magnus Fibronectin binding peptide
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
DE69734601T2 (de) * 1996-05-16 2006-08-03 The Texas A & M University System, College Station Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen
SE9602496D0 (sv) * 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
NZ336781A (en) * 1997-01-21 2002-10-25 Texas A & M Univ Sys Fibronectin binding protein compositions, antibodies thereto, and methods of use
AU1537699A (en) * 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)

Also Published As

Publication number Publication date
ATE422368T1 (de) 2009-02-15
EP1109577A1 (en) 2001-06-27
EP1109577A4 (en) 2002-03-13
JP2002523473A (ja) 2002-07-30
IL141639A0 (en) 2002-03-10
MXPA01002119A (es) 2003-03-27
CN1317976A (zh) 2001-10-17
CA2777661A1 (en) 2000-03-09
EP1109577B1 (en) 2009-02-11
CN1314450C (zh) 2007-05-09
DE69940404D1 (de) 2009-03-26
KR20010085745A (ko) 2001-09-07
CA2340304C (en) 2012-12-04
JP2011168607A (ja) 2011-09-01
AU5588999A (en) 2000-03-21
KR100644953B1 (ko) 2006-11-10
JP5460642B2 (ja) 2014-04-02
IL141639A (en) 2005-12-18
AU771426B2 (en) 2004-03-18
CA2777661C (en) 2014-10-21
CA2340304A1 (en) 2000-03-09
WO2000012131A1 (en) 2000-03-09
ES2322409T3 (es) 2009-06-19

Similar Documents

Publication Publication Date Title
BR9913340A (pt) Composição, vacina, e, processos de gerar uma resposta imune, e de inibir a colonização microbiana em um animal
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
DK0759774T3 (da) Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
TR199903053T2 (xx) Benzimidazol t�revleri.
ES2074563T3 (es) Procedimiento de preparacion de compuestos y metodo para el tratamiento de la septicemia y/o el choque septico.
AR016295A1 (es) Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
DE69224069D1 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
Erickson et al. Purification and partial characterization of a 65-kDa platelet aggregation-associated protein antigen from the surface of Streptococcus sanguis.
BR112018016359A2 (pt) biopesticidas para doença de requeima da batata
ATE427116T1 (de) Behandlung von bakteriellen infektionen
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
BR112021024010A2 (pt) Antibióticos macrocíclicos de amplo espectro
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
Tran et al. Targeting cell membrane adaptation as a novel antimicrobial strategy
BRPI0104510B8 (pt) peptídeos antibióticos da família das phylloseptinas isolados da secreção da pele de phylloseptina hypocondrialis e composição antimicrobiana relacionada
DE69413789D1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
KR950010898A (ko) 재조합 사람 혈청 알부민 약제학적 제제의 멸균법
ES2096988T3 (es) Organopolisiloxanos que contienen grupos hidrofilos.
Ahmed et al. Comparative study between Pure Bacterocin and Vancomycin on Biofilms of MRSA isolated from medical implants
Yamanaka et al. Cytolytic action of Vibrio vulnificus haemolysin on mast cells from rat peritoneal cavity
ATE285786T1 (de) Säugetierabkömmliche peptide zur behandlung von mikrobiellen infektionen
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
Chauhan et al. Differential roles for NOD2 in osteoblast inflammatory immune responses to bacterial pathogens of bone tissue

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]